BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18682102)

  • 1. Genetic origins of hyper-IgE syndrome.
    Minegishi Y; Karasuyama H
    Curr Allergy Asthma Rep; 2008 Sep; 8(5):386-91. PubMed ID: 18682102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
    Minegishi Y; Karasuyama H
    Int Immunol; 2009 Feb; 21(2):105-12. PubMed ID: 19088064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
    Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
    J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3.
    Paulson ML; Freeman AF; Holland SM
    Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):527-33. PubMed ID: 18978467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.
    Siegel AM; Stone KD; Cruse G; Lawrence MG; Olivera A; Jung MY; Barber JS; Freeman AF; Holland SM; O'Brien M; Jones N; Nelson CG; Wisch LB; Kong HH; Desai A; Farber O; Gilfillan AM; Rivera J; Milner JD
    J Allergy Clin Immunol; 2013 Dec; 132(6):1388-96. PubMed ID: 24184145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome.
    Woellner C; Gertz EM; Schäffer AA; Lagos M; Perro M; Glocker EO; Pietrogrande MC; Cossu F; Franco JL; Matamoros N; Pietrucha B; Heropolitańska-Pliszka E; Yeganeh M; Moin M; Español T; Ehl S; Gennery AR; Abinun M; Breborowicz A; Niehues T; Kilic SS; Junker A; Turvey SE; Plebani A; Sánchez B; Garty BZ; Pignata C; Cancrini C; Litzman J; Sanal O; Baumann U; Bacchetta R; Hsu AP; Davis JN; Hammarström L; Davies EG; Eren E; Arkwright PD; Moilanen JS; Viemann D; Khan S; Maródi L; Cant AJ; Freeman AF; Puck JM; Holland SM; Grimbacher B
    J Allergy Clin Immunol; 2010 Feb; 125(2):424-432.e8. PubMed ID: 20159255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children.
    Hagl B; Heinz V; Schlesinger A; Spielberger BD; Sawalle-Belohradsky J; Senn-Rauh M; Magg T; Boos AC; Hönig M; Schwarz K; Dückers G; von Bernuth H; Pache C; Karitnig-Weiss C; Belohradsky BH; Frank J; Niehues T; Wahn V; Albert MH; Wollenberg A; Jansson AF; Renner ED
    Pediatr Allergy Immunol; 2016 Mar; 27(2):177-84. PubMed ID: 26592211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyper-IgE syndrome.
    Minegishi Y
    Curr Opin Immunol; 2009 Oct; 21(5):487-92. PubMed ID: 19717292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.
    Boos AC; Hagl B; Schlesinger A; Halm BE; Ballenberger N; Pinarci M; Heinz V; Kreilinger D; Spielberger BD; Schimke-Marques LF; Sawalle-Belohradsky J; Belohradsky BH; Przybilla B; Schaub B; Wollenberg A; Renner ED
    Allergy; 2014 Jul; 69(7):943-53. PubMed ID: 24898675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Immunodeficiencies with Elevated IgE.
    Mogensen TH
    Int Rev Immunol; 2016; 35(1):39-56. PubMed ID: 25970001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of hyper IgE syndrome.
    Heimall J; Freeman A; Holland SM
    Clin Rev Allergy Immunol; 2010 Feb; 38(1):32-8. PubMed ID: 19452285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes.
    Freeman AF; Holland SM
    Pediatr Res; 2009 May; 65(5 Pt 2):32R-37R. PubMed ID: 19190525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.
    Saito M; Nagasawa M; Takada H; Hara T; Tsuchiya S; Agematsu K; Yamada M; Kawamura N; Ariga T; Tsuge I; Nonoyama S; Karasuyama H; Minegishi Y
    J Exp Med; 2011 Feb; 208(2):235-49. PubMed ID: 21300911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired memory B-cell development and antibody maturation with a skewing toward IgE in patients with STAT3 hyper-IgE syndrome.
    van de Veen W; Krätz CE; McKenzie CI; Aui PM; Neumann J; van Noesel CJM; Wirz OF; Hagl B; Kröner C; Spielberger BD; Akdis CA; van Zelm MC; Akdis M; Renner ED
    Allergy; 2019 Dec; 74(12):2394-2405. PubMed ID: 31269238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyper-IgE syndromes].
    He YY; Liu B; Xiao XP
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(11):892-896. PubMed ID: 29775011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome.
    Mócsai G; Gáspár K; Dajnoki Z; Tóth B; Gyimesi E; Bíró T; Maródi L; Szegedi A
    J Clin Immunol; 2015 Oct; 35(7):681-8. PubMed ID: 26453584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
    Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
    J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.
    Yanagimachi M; Ohya T; Yokosuka T; Kajiwara R; Tanaka F; Goto H; Takashima T; Morio T; Yokota S
    J Clin Immunol; 2016 Jul; 36(5):511-6. PubMed ID: 27091139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.
    Kreins AY; Ciancanelli MJ; Okada S; Kong XF; Ramírez-Alejo N; Kilic SS; El Baghdadi J; Nonoyama S; Mahdaviani SA; Ailal F; Bousfiha A; Mansouri D; Nievas E; Ma CS; Rao G; Bernasconi A; Sun Kuehn H; Niemela J; Stoddard J; Deveau P; Cobat A; El Azbaoui S; Sabri A; Lim CK; Sundin M; Avery DT; Halwani R; Grant AV; Boisson B; Bogunovic D; Itan Y; Moncada-Velez M; Martinez-Barricarte R; Migaud M; Deswarte C; Alsina L; Kotlarz D; Klein C; Muller-Fleckenstein I; Fleckenstein B; Cormier-Daire V; Rose-John S; Picard C; Hammarstrom L; Puel A; Al-Muhsen S; Abel L; Chaussabel D; Rosenzweig SD; Minegishi Y; Tangye SG; Bustamante J; Casanova JL; Boisson-Dupuis S
    J Exp Med; 2015 Sep; 212(10):1641-62. PubMed ID: 26304966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical manifestations of hyper IgE syndromes.
    Freeman AF; Holland SM
    Dis Markers; 2010; 29(3-4):123-30. PubMed ID: 21178271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.